A 40-week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL in Participants With Type 2 Diabetes Inadequately Controlled on Oral Anti Diabetic Drugs COMBINE 4

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar levels as compared to insulin glargine in people with type 2 diabetes who do not have their blood sugar properly controlled with other oral diabetes medicines. Participant will either get IcoSema or insulin glargine. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe insulin glargine in many countries. The study will last for about 11 months (47 weeks).

Start Date15 Feb 2024

Sponsor / Collaborator

Novo Nordisk A/S

NCT05435677

/ CompletedPhase 1

A Study Investigating the Pharmacokinetic Properties of a Single Dose of IcoSema Compared With Insulin Icodec and Semaglutide Given Separately in Chinese Participants With Type 2 Diabetes

This study will look at a new medicine, called IcoSema, for treatment of type 2 diabetes.
IcoSema is a combination of a new insulin, called insulin icodec, and a GLP-1 receptor analogue, called semaglutide.
Insulin icodec is a possible new medicine. That means that the medicine has not yet been approved by the authorities. Semaglutide is a medicine already approved by the authorities in the EU, USA, China and Japan.
The study will look at the way insulin icodec and semaglutide reach and stay in participants blood after injection when given together as IcoSema or alone as insulin icodec and semaglutide.
Participants will get each of the 3 medicines (IcoSema, insulin icodec and semaglutide) at 3 different timepoints:
The order in which participants get them is decided by chance. Participants will get the 3 medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks.
The study will last for about 19 to 26 weeks. Participants will have 31 or 32 visits to the clinic. 3 of the visits will be in-house visits, meaning that participants will stay at the clinic for 5 or 6 days (4 or 5 nights).
Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Start Date22 Jun 2022

Sponsor / Collaborator

Novo Nordisk A/S

NCT05352815

/ CompletedPhase 3

A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.
Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.
Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.
The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.
Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.

Start Date01 Jun 2022

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Icodec Insulin/Semaglutide

100 Translational Medicine associated with Icodec Insulin/Semaglutide

100 Patents (Medical) associated with Icodec Insulin/Semaglutide

Literatures (Medical) associated with Icodec Insulin/Semaglutide

02 Jun 2026·Zhonghua yi xue za zhi

[Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults].

Article

Author: Zang, L ; Zhang, S C ; Cheng, Y ; Hu, X ; Mu, Y M

The prevalence of type 2 diabetes mellitus has been rising continuously in China. However, glycemic control rates remain suboptimal, posing a significant public health challenge. Although traditional intensive insulin strategies are effective in improving glycemic control, they are often associated with risks such as hypoglycemia and weight gain. Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) offer complementary mechanisms of action, enhancing efficacy and safety while simplifying treatment regimens, making them a key focus of clinical development. Insulin icodec/semaglutide fixed-ratio combination (IcoSema), the first once-weekly dual-component preparation combining a basal insulin and a GLP-1RA, utilizes advanced formulation technology to achieve stable co-formulation of the ultra-long-acting once-weekly basal insulin and the once-weekly GLP-1RA, with the two components acting in a complementary and synergistic manner. The Phase 3 COMBINE clinical trial program demonstrated that, compared with insulin icodec, semaglutide(1.0 mg), or basal-bolus insulin regimens, IcoSema provides superior or equivalent glycemic control, and the risk of clinically significant or severe hypoglycemic events is comparable to that of semaglutide(1.0 mg). Once-weekly administration helps to simplify the treatment regimen and improve treatment adherence. The clinical application of IcoSema is expected to alleviate the dilemma in Chinese type 2 diabetes management of balancing effective glycemic control with safety and simplicity, offering a new therapeutic option for patients requiring insulin intensification that combines efficacy, safety, and convenience.

01 May 2026·DIABETES OBESITY & METABOLISM

Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis

Review

Author: Olivier Bourron MD ; Damien Denimal PhD

Abstract:

Aims:

Once‐weekly ( OW ) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.

Materials and Methods:

We systematically searched PubMed , WoS , ClinicalTrials.gov and EU Clinical Trials databases up to June 2025 for randomized controlled trials ( RCTs ) evaluating OW insulins in type 2 diabetes. Primary outcomes included efficacy ( HbA1c , fasting plasma glucose ( FPG ), time‐in‐range ( TIR ), time‐above‐range) and safety outcomes (body weight, hypoglycaemia, time‐below‐range). Data were analysed using both frequentist and Bayesian approaches.

Results:

Among 435 screened records, 16 RCTs were included. OW insulins achieved a greater reduction in HbA1c compared to once‐daily insulin or semaglutide (pooled mean difference: −0.12%, 95% CI : −0.19 to −0.04, p = 0.007). TIR was significantly longer in the OW insulin group (+2.41% of total time, 95% CI : 1.13 to 3.69, p = 0.002), while FPG changes were comparable (−3.37 mg/ dL , 95% CI : −7.95 to 1.21 mg/ dL , p = 0.14). Body weight changes were generally similar, but excluding trials using IcoSema revealed a modest weight gain (+0.33 kg, 95% CI : 0.04 to 0.62, p = 0.030). The incidence of clinically significant or severe hypoglycaemia did not differ between groups (pooled incidence rate ratio: 1.04, 95% CI : 0.79 to 1.28, p = 0.75). Meta‐regression confirmed consistent effect sizes across OW insulin types, treatment durations and prior insulin regimens.

Conclusions:

OW insulins modestly improve glycaemic control without increasing hypoglycaemia risk, though slight weight gain may occur.

01 Apr 2026·Diabetes Therapy

Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis

Article

Author: Benamar, Malik ; Kandalam, Saikrishna ; Le Reun, Corinne ; Rengger, Lauren ; Gupta, Palvi ; Nair, Sunita

INTRODUCTION:

For people with type 2 diabetes (T2D), combination therapy with a basal insulin and a glucagon-like peptide 1 receptor agonist (GLP-1 RA) can improve glycaemic control, lower hypoglycaemia risk, and improve adherence. IcoSema is the first once-weekly combination of basal insulin and GLP-1 RA in a single injection. To compare once-weekly IcoSema and once-daily IDegLira for the management of T2D in the absence of head-to-head trials, we performed a network meta-analysis (NMA).

METHODS:

A systematic literature review was conducted in November 2023, updated in August 2025, to identify randomised controlled trials (RCTs) of people with T2D, investigating basal insulin and GLP-1 RA combination therapies. Data were extracted for change from baseline in glycated haemoglobin (HbA_1c), body weight, systolic blood pressure, end-of-treatment basal insulin dose, rate ratio (RR) of clinically significant or severe hypoglycaemia and discontinuation due to adverse events (DDAEs). The NMA scope included multinational RCTs with evidence at 52 ± 4 weeks. Fixed and random effects Bayesian NMAs were fitted.

RESULTS:

At 52 weeks, compared with IDegLira, IcoSema was associated with significantly greater HbA_1c reduction (- 0.4%; 95% credible interval [CrI] - 0.56, - 0.24), significantly greater body weight reduction (- 3.2 kg; 95% CrI - 3.91, - 2.5), significantly lower daily insulin dose (- 9 units/day; 95% CrI - 13, - 5) and significantly lower rates of clinically significant or severe hypoglycaemia (RR 0.35; 95% CrI 0.26, 0.46). There was no difference in the odds of DDAEs. No 52 ± 4-week IGlarLixi trials were identified.

CONCLUSION:

These results indicate that once-weekly IcoSema is an efficacious treatment option for adults with T2D requiring insulin intensification. IcoSema was associated with improved glycaemic control, weight reduction, and lower hypoglycaemia risk compared with once-daily IDegLira, as well as a reduction in insulin and injection requirements. Weekly IcoSema offers the potential to reduce treatment burden and increase adherence, thereby improving long-term disease control and patient outcomes.

News (Medical) associated with Icodec Insulin/Semaglutide

19 Jul 2026

·www.biospace.com

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, further expanding its collaboration with global healthcare company Novo Nordisk to improve access to innovative diabetes treatments through AI-powered chronic disease management services. China is the first market globally to commercialize Kyinsu ® , making Fangzhou one of the product's key launch partners. Leveraging its AI-enabled chronic disease management ecosystem and nationwide pharmaceutical supply chain, the Company aims to accelerate patient access to the new therapy while supporting long-term treatment management. Kyinsu ® is a milestone product developed under Novo Nordisk's innovation program. The once-weekly therapy combines insulin icodec, the world's first once-weekly basal insulin, with semaglutide, a widely used GLP-1 receptor agonist, to address multiple pathophysiological mechanisms of type 2 diabetes 1,2 . By reducing injections from daily to once weekly, the treatment is designed to lessen the burden of insulin therapy while maintaining effective glycemic control 3 . China remains the world's largest diabetes market, with approximately 148 million adults living with diabetes, accounting for roughly one-quarter of the global adult diabetes population 4 . Although insulin transformed diabetes from a fatal disease into a manageable chronic condition more than a century ago, daily injections continue to present challenges for many patients. Studies have shown that most insulin users would prefer a treatment requiring fewer injections 5 , while concerns over hypoglycemia and weight gain remain important barriers to long-term treatment adherence 6 . ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Fangzhou emphasized that, while the introduction of innovative medicines is a critical milestone, clinical innovation alone cannot fully optimize patient outcomes without sustained disease management. Built around its AI+H2H (Hospital-to-Home) ecosystem, the Company’s platform integrates digital health services with medical innovation to support patients throughout their treatment journey. Its AI Health Manager and AI Medication Assistant help physicians deliver continuous follow-up, medication guidance, and personalized health management, while educational content distributed through the platform seeks to improve disease awareness and long-term adherence. The launch also reflects the companies’ broader strategic collaboration efforts to integrate innovative medicines with digital healthcare services. Fangzhou will continue working with leading global biopharmaceutical companies to accelerate the adoption of breakthrough therapies while strengthening its AI-powered chronic disease management platform. Fangzhou remains committed to its mission of delivering trusted, long-term healthcare services by combining medical innovation with intelligent digital care, contributing to the goals of the Healthy China 2030 initiative. This press release is intended solely to communicate scientific and market information. It does not constitute a recommendation, promotion, or advertisement for any medication or treatment. Patients should consult qualified healthcare professionals regarding medical treatment decisions. References: 1.Westergaard L, et al. Clin Drug Investig. 2024 Nov;44(11):849-861. 2. 3.张赛春, 臧丽, 程愈, 等. 中华医学杂志, 2026, 106(20): 1969-1976 4.IDF Diabetes Atlas, 11th edition, 2025 5.Peyrot M, et al. Diabetes Med 2012; 29:682–689 6.Lee DSU, et al. Diabetol Metab Syndr. 2022 Jan 15;14(1):12. About Fangzhou Inc. Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians (as of December 31, 2025). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit . Media Contact For further inquiries or interview requests, please contact: Xingwei Zhao Director of Public Relations Email: pr@jianke.com Disclaimer: This press release contains forward ‑ looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

27 May 2026

·www.novonordisk.com

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions

Plainsboro, NJ, US and Bagsværd, Denmark, 27 May 2026 – Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association ® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in an ADA Scientific Session. 1 A total of 40 abstracts will be presented, including phase 2 data assessing the safety and efficacy of investigational once-weekly injectable zenagamtide, as well as new data for Ozempic ® and Wegovy ® , building on the growing body of clinical evidence for semaglutide across multiple cardiometabolic conditions. 2 “The ADA’s 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. “As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases.” On Sunday, 7 June 2026, Novo Nordisk will host an R&D investor event on the science and abstracts presented at the conference. The event will be accessible via a live webcast on the Novo Nordisk investor website . Select Novo Nordisk abstracts to be presented at The ADA’s 2026 Scientific Sessions, 5-8 June, New Orleans: Data for investigational uses of semaglutide and investigational medicines containing CagriSema, zenagamtide, IcoSema, and efruxifermin. Symposium: • REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema – Sunday, 7 June; 4:30–6:00 pm CDT Novo Nordisk poster and oral presentations: CagriSema Zenagamtide Wegovy ® (semaglutide injection and tablets) Ozempic ® (semaglutide injection and tablets) Semaglutide for MASH Insulin Icodec • 1750-P Glucodynamics and Hypoglycemia Risk During Exercise or Fasting in Individuals with T2D Receiving Once-Weekly Basal Insulin Icodec – Saturday, 6 June; 12:30–1:30 pm CDT IcoSema Efruxifermin • 1294-OR Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial – Monday, 8 June; 2:45–3:00 pm CDT Cross-product • 1696-P Effect of Semaglutide on COVID-19-Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials – Sunday, 7 June; 12:30–1:30 pm CDT Non-product 9 additional abstracts being presented at ADA will cover data related to cardiometabolic diseases, including type 2 diabetes, obesity, kidney, and liver disease. CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States. Safety and efficacy are not established, and there is no guarantee that these investigational medicines will become commercially available for the uses under clinical investigation. About semaglutide Semaglutide is a GLP-1 receptor agonist (GLP-1 RA) that is structurally similar to the naturally occurring hormone GLP-1. It works by selectively binding to and activating the GLP-1 receptor. Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease, and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy ® (semaglutide) injection 2.4 mg, Wegovy ® HD (semaglutide) injection 7.2 mg, Wegovy ® (semaglutide) tablets 25 mg, Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Ozempic ® (semaglutide) tablets 4 mg or 9 mg. About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide. 1 About zenagamtide Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Zenagamtide is under investigation for oral and subcutaneous administration. About type 2 diabetes Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 3 According to 2023 CDC data, in the United States, 40.1 million people have diabetes, with type 2 diabetes representing 90% to 95%, or an estimated 36 – 38 million people living with type 2 diabetes, making it the most common form of the disease. 3,4 About obesity Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. 5-7 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. 5,7 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment. 8,9 About Novo Nordisk Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit novonordisk.com and novonordiskus.com, and follow us on Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: References © 2026 Novo Nordisk All rights reserved. US26SEMO01000 May 2026

Phase 2Drug ApprovalPhase 3

16 Jan 2026

·endpoints.news

European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA

The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations last year, 38 were for new active substances — novel molecules, as opposed to reformulations or generics, for instance — according to the report. That figure markedly lags the 53 new treatments greenlit by the FDA in 2025. The total number was second only to the 114 drugs recommended in 2024. “If you look back over the past 15 years, you will see the number waxes and wanes, but there was a big dip during Covid-19,” EMA chief medical officer Steffen Thirstrup said in a press briefing on Thursday. “Some of what we saw [in 2024] was…a wave of things that had been postponed and protracted during Covid-19, and 104 is still a very high number of approvals from a European perspective.” Several new products were approved in the US last year but are still awaiting European authorization. These include Milestone Pharmaceuticals’ Cardamyst, approved in the US in December for an arrhythmia disorder called paroxysmal supraventricular tachycardia. Milestone has submitted an application in the EU for the drug under the name Tachymist, but a decision is not expected until the first quarter of 2027, showing just how long the delay between the two regulators can be. At least one product was approved in Europe but not in the US, however. The European agency recommended Novo Nordisk’s fixed-dose combination of insulin icodec and semaglutide for type 2 diabetes in September, and it was approved in Europe as Kyinsu in November. US approval of Kyinsu is not imminent. The FDA rejected insulin icodec due to manufacturing concerns in 2024. Novo has since resubmitted insulin icodec in the US, but will have to wait for that decision before filing the fixed-dose combination. As a combination of approved drugs, Kyinsu would not count as a novel medicine, however. Endocrinology was the most popular therapeutic area for medicine approvals in Europe last year. The EMA recommended 29 products for endocrine disorders, including three new treatments. These were Bayer’s Lynkuet for menopause symptoms, Sanofi’s Teizeild for type 1 diabetes and Amgen’s Tepezza for thyroid eye disease. Looking to the year ahead, the EMA said it expects continued innovation in weight management and diabetes. The agency has received the first application for a generic version of Novo Nordisk’s older GLP-1 agonist product liraglutide for both indications. Meanwhile, its safety committee is also looking into possible interactions between the drug class and contraceptive pills.

Drug Approval

100 Deals associated with Icodec Insulin/Semaglutide

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	European Union	Novo Nordisk A/S	24 Nov 2025
Diabetes Mellitus, Type 2	Iceland	Novo Nordisk A/S	24 Nov 2025
Diabetes Mellitus, Type 2	Liechtenstein	Novo Nordisk A/S	24 Nov 2025
Diabetes Mellitus, Type 2	Norway	Novo Nordisk A/S	24 Nov 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05352815 (COMBINE 1, NEWS \| Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	1,291	IcoSema	mdmtetxbvu(ngkgnsdypy) = lacpnwkntr zgruoohfxa (zdkjoghblx, 0.03) View more	Positive	05 Jun 2025
				单独基础胰岛素icodec	mdmtetxbvu(ngkgnsdypy) = bcraompnmf zgruoohfxa (zdkjoghblx, 0.03) View more
NCT05352815 (COMBINE 1, CTgov)	Phase 3	Diabetes Mellitus, Type 2	1,291	IcoSema (IcoSema)	iztkifcbtj(prbtgfaknc) = ksqtjgvzlv zlbnzfjosp (ituppobslg, 0.99) View more	-	03 Apr 2025
				Insulin icodec (Insulin Icodec)	iztkifcbtj(prbtgfaknc) = vhehbpnzvn zlbnzfjosp (ituppobslg, 1.01) View more
NCT05259033 (COMBINE 2, Pubmed \| Diabetologia)	Phase 3	Diabetes Mellitus, Type 2 GLP-1 receptor agonist	683	IcoSema	fycsddauqj(gkmqdinudk) = iooqtvpwph pxtlvolqxc (nnxucxghqg )	Positive	01 Apr 2025
NCT05259033 (COMBINE 2, CTgov)	Phase 3	Diabetes Mellitus, Type 2	683	IcoSema (IcoSema)	mqraaxcgzy(sqjtgvnuqy) = avdphfueqt jvlfmaxlwu (slgtpltupi, 0.91) View more	-	17 Jan 2025
				Semaglutide 1 mg (Semaglutide)	mqraaxcgzy(sqjtgvnuqy) = nrznxmpvjb jvlfmaxlwu (slgtpltupi, 0.96) View more
NCT05013229 (COMBINE 3, GlobeNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	679	IcoSema	itmuyicyla(bdoqrxblok) = rkxftzffhr nxyaagauug (stzdihjgga ) View more	Positive	08 Jan 2024
				Insuling glargine/insulin aspart	itmuyicyla(bdoqrxblok) = fyjsmxmudn nxyaagauug (stzdihjgga ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis